| chronic pain (diagnosis)
Prialt vs Nucynta ER
Side-by-side clinical, coverage, and cost comparison for chronic pain (diagnosis).Deep comparison between: Prialt vs Nucynta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNucynta has a higher rate of injection site reactions vs Prialt based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nucynta but not Prialt, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Prialt
Nucynta
At A Glance
Intrathecal infusion
Continuous infusion
N-type calcium channel blocker
Oral
Twice daily
Opioid agonist / NRI
Indications
- chronic pain (diagnosis)
- chronic pain (diagnosis)
- Diabetic peripheral neuropathy
Dosing
chronic pain (diagnosis) Initiate at no more than 2.4 mcg/day (0.1 mcg/hr) intrathecally; titrate by up to 2.4 mcg/day at intervals no more than 2-3 times per week; maximum recommended dose 19.2 mcg/day (0.8 mcg/hr).
chronic pain (diagnosis), Diabetic peripheral neuropathy Initiate at 50 mg orally every 12 hours in opioid-naive patients; titrate by 50 mg increments no more than twice daily every three days; maximum total daily dose 500 mg.
Moderate hepatic impairment Initiate at 50 mg no more than once every 24 hours; maximum 100 mg per day; regularly evaluate for respiratory and CNS depression.
Contraindications
- Known hypersensitivity to ziconotide or any formulation component
- Any concomitant treatment or medical condition rendering intrathecal administration hazardous
- Infection at the microinfusion injection site
- Uncontrolled bleeding diathesis
- Spinal canal obstruction that impairs circulation of CSF
- Pre-existing history of psychosis
- Significant respiratory depression
- Acute or severe bronchial asthma or hypercarbia in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to tapentadol or any other ingredient of the product
- Concurrent use of MAOIs or use within the last 14 days
Adverse Reactions
Most common (>=25%) dizziness, nausea, confusional state, nystagmus
Serious acute renal failure, atrial fibrillation, cerebrovascular accident, sepsis, meningitis, psychotic disorder, suicidal ideation, respiratory distress, rhabdomyolysis, fatal aspiration pneumonia, suicide attempt
Postmarketing hypersensitivity reactions including angioedema, bullous dermatitis, skin ulcers, skin exfoliation, burning skin sensation
Most common (>=10%) Nausea, constipation, dizziness, headache, somnolence, vomiting
Serious Respiratory depression, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, neonatal opioid withdrawal syndrome
Postmarketing Hallucination, suicidal ideation, panic attack, anaphylaxis, androgen deficiency, hyperalgesia, allodynia, hypoglycemia, opioid-induced esophageal dysfunction
Pharmacology
Ziconotide is an N-type calcium channel blocker; it binds to N-type calcium channels on primary nociceptive afferent nerves in the dorsal horn of the spinal cord, blocking excitatory neurotransmitter release from afferent nerve terminals and producing antinociception.
Tapentadol is a centrally-acting synthetic analgesic that acts as a mu-opioid receptor (MOR) agonist and norepinephrine reuptake inhibitor (NRI); analgesia in animal models is derived from both properties, though the exact mechanism in humans is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Prialt
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (0/12)
Nucynta
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Prialt
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Nucynta
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (7/8)
Humana
Prialt
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Nucynta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$20/fillfill
Prialt Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Nucynta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PrialtView full Prialt profile
NucyntaView full Nucynta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.